Stocktoria
INTERPACE BIOSCIENCES, INC. IDXG
INTERPACE BIOSCIENCES, INC. (IDXG) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $38.7M at a 63.5% net margin.
Price from month-end closes (Yahoo) — for reference, not real-time.
How it ranks in Manufacturing · percentile among 1829 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.142 |
| Retained earnings / assets | -6.23 |
| EBIT / assets | 0.121 |
| Equity / liabilities | 1.949 |
Detailed pages
Sector peers · similar-size Manufacturing companies
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| IDXG | INTERPACE BIOSCIENCES, INC. | 4/9 | -16.52 | 1.9 | -17.5% |
| UTMD | UTAH MEDICAL PRODUCTS INC | 3/9 | — | — | -5.8% |
| CTSO | Cytosorbents Corp | 3/9 | — | — | +4.1% |
| KRMD | KORU Medical Systems, Inc. | 4/9 | -0.06 | — | +22.2% |
| SSII | SS Innovations International, Inc. | 4/9 | -0.09 | — | +105.7% |
| OBIO | Orchestra BioMed Holdings, Inc. | 5/9 | -7.02 | — | — |
| SNWV | SANUWAVE Health, Inc. | 6/9 | -19.06 | 6.3 | +35% |
FAQ
Is IDXG financially healthy?
INTERPACE BIOSCIENCES, INC.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does IDXG pay a dividend?
No, INTERPACE BIOSCIENCES, INC. does not currently pay a dividend.
How profitable is IDXG?
In FY2025, INTERPACE BIOSCIENCES, INC. had a net margin of 63.5% and a return on equity of 109.9%.
Source: SEC EDGAR filings · CIK 0001054102 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.